Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent

Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections, treatment of Lyme disease and eradication of gastric infection with Helicobacter pylori. Extensive preclinical and clinical data demonstrate a pote...

Full description

Bibliographic Details
Main Authors:	Van Nuffel, An MT, Sukhatme, Vidula, Pantziarka, Pan, Meheus, Lydie, Sukhatme, Vikas P, Bouche, Gauthier
Format:	Online
Language:	English
Published:	Cancer Intelligence 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341996/

id	pubmed-4341996
recordtype	oai_dc
spelling	pubmed-43419962015-02-27 Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent Van Nuffel, An MT Sukhatme, Vidula Pantziarka, Pan Meheus, Lydie Sukhatme, Vikas P Bouche, Gauthier Conference Report Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections, treatment of Lyme disease and eradication of gastric infection with Helicobacter pylori. Extensive preclinical and clinical data demonstrate a potential role for CAM to treat various tumours in combination with conventional treatment. The mechanisms of action underlying the anti-tumour activity of CAM are multiple and include prolonged reduction of pro-inflammatory cytokines, autophagy inhibition, and anti-angiogenesis. Here, we present an overview of the current preclinical (in vitro and in vivo) and clinical evidence supporting the role of CAM in cancer. Overall these findings justify further research with CAM in many tumour types, with multiple myeloma, lymphoma, chronic myeloid leukaemia (CML), and lung cancer having the highest level of evidence. Finally, a series of proposals are being made to further investigate the use of CAM in clinical trials which offer the greatest prospect of clinical benefit to patients. Cancer Intelligence 2015-02-24 /pmc/articles/PMC4341996/ /pubmed/25729426 http://dx.doi.org/10.3332/ecancer.2015.513 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Van Nuffel, An MT Sukhatme, Vidula Pantziarka, Pan Meheus, Lydie Sukhatme, Vikas P Bouche, Gauthier
spellingShingle	Van Nuffel, An MT Sukhatme, Vidula Pantziarka, Pan Meheus, Lydie Sukhatme, Vikas P Bouche, Gauthier Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
author_facet	Van Nuffel, An MT Sukhatme, Vidula Pantziarka, Pan Meheus, Lydie Sukhatme, Vikas P Bouche, Gauthier
author_sort	Van Nuffel, An MT
title	Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
title_short	Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
title_full	Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
title_fullStr	Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
title_full_unstemmed	Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent
title_sort	repurposing drugs in oncology (redo)—clarithromycin as an anti-cancer agent
description	Clarithromycin (CAM) is a well-known macrolide antibiotic available as a generic drug. CAM is traditionally used for many types of bacterial infections, treatment of Lyme disease and eradication of gastric infection with Helicobacter pylori. Extensive preclinical and clinical data demonstrate a potential role for CAM to treat various tumours in combination with conventional treatment. The mechanisms of action underlying the anti-tumour activity of CAM are multiple and include prolonged reduction of pro-inflammatory cytokines, autophagy inhibition, and anti-angiogenesis. Here, we present an overview of the current preclinical (in vitro and in vivo) and clinical evidence supporting the role of CAM in cancer. Overall these findings justify further research with CAM in many tumour types, with multiple myeloma, lymphoma, chronic myeloid leukaemia (CML), and lung cancer having the highest level of evidence. Finally, a series of proposals are being made to further investigate the use of CAM in clinical trials which offer the greatest prospect of clinical benefit to patients.
publisher	Cancer Intelligence
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341996/
_version_	1613193025561821184

Repurposing Drugs in Oncology (ReDO)—clarithromycin as an anti-cancer agent

Similar Items